Purpose: Neoadjuvant systemic therapy with dual HER2-blockade, trastuzumab and pertuzumab, combined with chemotherapy has become a standard approach in patients with HER2-positive (HER2+) breast cancer (BC). However, the variability in treatment outcomes, such as pathological complete response (pCR) or relapse rates, underscores the need to identify predictive factors to optimize therapeutic strategies. This st...
Superoxide anion, along with other reactive species, is involved in many toxicological processes, as well as in a number of pathophysiological phenomena. Superoxide dismutase mimetics (SODm), i.e., synthetic compounds that mimic the functional properties of superoxide dismutase converting O2 •– to H2O2 and O2, have thus emerged as prospective pharmaceutical candidates to overcome toxicity in oxidative stress-re...